Experimental Drug Makes the Immune System Revolt Against Cancer
A biotech company, founded by researchers from the University of Munich, has developed a fascinating way to make the immune system fight cancer.
On Thursday, Micromet Inc. announced that its experimental drug, MT103, had impressive results in a test upon seven Non-Hodgkin’s Lymphoma patients. All of them had failed at least three conventional treatments, but showed signs of recovery after receiving doses of a two-headed antibody.
This entry was posted on Saturday, June 7th, 2008 at 10:06 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.